HRP20191412T1 - Pripravci s kontroliranim oslobađanjem i postupci njihove upotrebe - Google Patents
Pripravci s kontroliranim oslobađanjem i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20191412T1 HRP20191412T1 HRP20191412T HRP20191412T1 HR P20191412 T1 HRP20191412 T1 HR P20191412T1 HR P20191412 T HRP20191412 T HR P20191412T HR P20191412 T1 HRP20191412 T1 HR P20191412T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation according
- oil
- surfactant
- preparation
- colloidal silica
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 3
- 238000013270 controlled release Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 claims 20
- 239000003921 oil Substances 0.000 claims 9
- 235000019198 oils Nutrition 0.000 claims 9
- 239000013543 active substance Substances 0.000 claims 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 7
- 239000008119 colloidal silica Substances 0.000 claims 7
- 239000004094 surface-active agent Substances 0.000 claims 7
- 230000002209 hydrophobic effect Effects 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- -1 aminoglycosides Chemical class 0.000 claims 3
- 229930182555 Penicillin Natural products 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000004182 Tylosin Substances 0.000 claims 2
- 229930194936 Tylosin Natural products 0.000 claims 2
- 229940126575 aminoglycoside Drugs 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229960003326 cloxacillin Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229960004059 tylosin Drugs 0.000 claims 2
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 claims 2
- 235000019375 tylosin Nutrition 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002280 amphoteric surfactant Substances 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 229960004350 cefapirin Drugs 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 1
- 229940093471 ethyl oleate Drugs 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 229940057995 liquid paraffin Drugs 0.000 claims 1
- 208000004396 mastitis Diseases 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 150000002960 penicillins Chemical class 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- 150000003952 β-lactams Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lubricants (AREA)
Claims (16)
1. Pripravak za intramamarnu primjenu,
pripravak sadrži terapeutski učinkovitu količinu najmanje jednog aktivnog sredstva, i
bazu konfiguriranu da osigura kontrolirano oslobađanje najmanje jednog aktivnog sastojka, te baza uključuje,
količinu hidrofobne koloidne silike;
najmanje jedno ulje; i
najmanje jedan surfaktant,
pri čemu aktivno sredstvo je antibiotik;
pri čemu je viskoznost pripravka ispod 1000 mPas pri brzini smicanja od 100 1/s i pri temperaturi od 20°C, i
pri čemu su hidrofobna koloidna silika i aktivno sredstvo dispergirani u ulju.
2. Pripravak prema patentnom zahtjevu 1 naznačen time što je antibiotsko aktivno sredstvo
a. odabrano iz skupine koja se sastoji od beta-laktama, penicilina, cefalosporina, aminoglikozida, kinolona, sulfonamida, tetraciklina i makrocikličkog antibiotika; i/ili
b. odabrano iz skupine koja se sastoji od kloksacilina, tilozina, cefapirina i njihovih kombinacija.
3. Pripravak prema patentnom zahtjevu 1 naznačen time što pripravak sadrži najmanje dva aktivna sredstva, a kombinacija aktivnog sredstva se bira od:
- amoksicilina i klavulanske kiseline;
- penicilinskog aktivnog sredstva i aminoglikozida;
- kloksacilina i tilozina;
- antibiotika i nesteroidnog protuupalnog lijeka.
4. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 3 naznačen time što hidrofobna koloidna silika je pirogena koloidna silika.
5. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 4 naznačen time što koncentracija hidrofobne koloidne silike iznosi između 0.1-5% m/m, ili između 1-3% m/m.
6. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 5 naznačen time što surfaktant ima HLB između 0.5 i 30, ili HLB između 4 i 16.
7. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 6 naznačen time što je surfaktant:
a. anionski, kationski, amfoterni ili neionski surfaktant; ili
b. neionski surfaktant i odabran je iz skupine koju čine sorbitan esteri, polioksietilen sorbitan esteri masnih kiselina, derivati polioksietilen ricinusovog ulja, polioksietilen stearati, polietilen oksid monooleat i njihove kombinacije.
8. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 7 naznačen time što je koncentracija surfaktanta između 0.01 do 10 % m/m.
9. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 8 naznačen time što omjer hidrofobne koloidne silike prema surfaktantu u bazi iznosi između 1:100 i 500:1, ili između 1:5 i 6:1.
10. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 9 naznačen time što baza sadrži više od jednog surfaktanta.
11. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 10 naznačen time što viskoznost ulja iznosi:
a. između 1 do 100 mPas pri 20°C; i/ili
b. manje od 40 mPas pri 20°C.
12. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 11 naznačen time što je ulje odabrano iz skupine koja se sastoji od triglicerida srednjeg lanca, lakog tekućeg parafina, etil oleata i sezamovog ulja.
13. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 12 naznačen time što je gustoća ulja između 0.80 i 0.99 g/cm3.
14. Pripravak prema bilo kojem od patentnih zahtjeva 1 do 13 naznačen time što pripravak ima viskoznost ispod 300 mPas pri brzini smicanja od 100 1/s i temperaturi od 20°C, ili viskoznost ispod 150 mPas pri brzini smicanja od 100 1/s i temperaturi od 20°C.
15. Postupak za proizvodnju pripravka prema bilo kojem od patentnih zahtjeva 1 do 14 naznačen time što uključuje korake:
a) miješanje ulja i surfaktanta u spremniku da se dobije homogena smjesa ulja;
b) dispergiranje aktivnog sredstva u smjesi ulja; i
c) naknadno dodavanje hidrofobne koloidne silike u smjesu ulja.
16. Uporaba pripravka prema bilo kojem od patentnih zahtjeva 1 do 15 naznačena time što je za proizvodnju lijeka za upotrebu u liječenju ili prevenciji pred kliničkog ili kliničkog mastitisa kod životinje kojoj je to potrebno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ59844312 | 2012-02-27 | ||
| PCT/NZ2013/000022 WO2013129944A1 (en) | 2012-02-27 | 2013-02-27 | Controlled release compositions and their methods of use |
| EP13755420.0A EP2819699B2 (en) | 2012-02-27 | 2013-02-27 | Controlled release compositions and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191412T1 true HRP20191412T1 (hr) | 2019-11-15 |
Family
ID=49083030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191412 HRP20191412T1 (hr) | 2012-02-27 | 2019-08-02 | Pripravci s kontroliranim oslobađanjem i postupci njihove upotrebe |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10828311B2 (hr) |
| EP (1) | EP2819699B2 (hr) |
| JP (1) | JP6271443B2 (hr) |
| KR (1) | KR102100271B1 (hr) |
| CN (2) | CN104244983A (hr) |
| AU (1) | AU2013201147A1 (hr) |
| BR (1) | BR112014021218A2 (hr) |
| CA (1) | CA2865555C (hr) |
| CL (1) | CL2014002227A1 (hr) |
| CO (1) | CO7061074A2 (hr) |
| CR (1) | CR20140396A (hr) |
| DK (1) | DK2819699T3 (hr) |
| DO (1) | DOP2014000195A (hr) |
| ES (1) | ES2740958T3 (hr) |
| HR (1) | HRP20191412T1 (hr) |
| HU (1) | HUE045495T2 (hr) |
| MX (1) | MX366726B (hr) |
| NI (1) | NI201400096A (hr) |
| PH (1) | PH12014501919A1 (hr) |
| PL (1) | PL2819699T3 (hr) |
| PT (1) | PT2819699T (hr) |
| RU (1) | RU2627429C2 (hr) |
| SI (1) | SI2819699T1 (hr) |
| SV (1) | SV2014004796A (hr) |
| WO (1) | WO2013129944A1 (hr) |
| ZA (1) | ZA201406267B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY172561A (en) * | 2012-07-17 | 2019-12-03 | Bayer New Zealand Ltd | Injectable antibiotic formulations and their methods of use |
| RU2019123307A (ru) * | 2017-01-20 | 2021-02-20 | М Эт П Фарма Аг | Фармацевтические композиции для назального введения для снижения рисков воздействия загрязнителей воздуха |
| US20220125798A1 (en) * | 2019-03-06 | 2022-04-28 | Zoetis Services Llc | Ready-to-use injectable formulations |
| CN114847280A (zh) * | 2022-07-07 | 2022-08-05 | 山东实力农业股份有限公司 | 一种包含脂肽的生物刺激剂组合物的制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3234086A (en) | 1961-05-12 | 1966-02-08 | Univ Iowa State Res Found Inc | Antibiotic bloat control composition and method of using same |
| US3252859A (en) * | 1962-10-24 | 1966-05-24 | Masti Kure Company Inc | Colloidal silica-oil composition and method of using same |
| GB1547164A (en) † | 1975-08-14 | 1979-06-06 | Beecham Group Ltd | Veterinary compositions |
| IL58462A0 (en) | 1978-10-27 | 1980-01-31 | Beecham Group Ltd | Intramammary compositions comprising a penicillin |
| IL58461A0 (en) | 1978-10-27 | 1980-01-31 | Beecham Group Ltd | Intramammary compositions comprising a clavulanic acid salt |
| EP0058015A3 (en) * | 1981-02-05 | 1982-08-25 | Beecham Group Plc | Treatment of infections |
| JPS60169431A (ja) * | 1984-02-14 | 1985-09-02 | Nippon Zenyaku Kogyo Kk | β−ラクタム環を有する化合物を含有する安定な抗菌剤及びその製造法 |
| JPS6289617A (ja) * | 1985-08-12 | 1987-04-24 | ウイリアム ガウフ タツカ− | 薬剤組成物およびその調製方法 |
| EP0212875A3 (en) | 1985-08-12 | 1988-06-15 | William Gough Tucker | Medicinal composition and method of making same |
| GB8531609D0 (en) | 1985-12-23 | 1986-02-05 | Beecham Group Plc | Compounds |
| US4980175A (en) | 1989-01-03 | 1990-12-25 | Leonard Chavkin | Liquid orally administrable compositions based on edible oils |
| US6060592A (en) | 1990-01-11 | 2000-05-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same |
| US5122377A (en) | 1990-11-19 | 1992-06-16 | A.H. Robins, Company, Incorporated | Oral delivery system for veterinary drugs |
| GB2338896B (en) * | 1998-07-02 | 2003-05-21 | Reckitt & Colmann Prod Ltd | Chewable Capsules |
| US20020009478A1 (en) | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| US6787342B2 (en) * | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
| US20040033938A1 (en) * | 2000-09-12 | 2004-02-19 | Britten Nancy J. | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| WO2003063877A1 (en) * | 2002-02-01 | 2003-08-07 | Akzo Nobel N.V. | Cefquinome composition for intra-mammary administration in cattle |
| AU2003224419A1 (en) | 2002-02-20 | 2003-09-09 | Strides Arcolab Limited | Orally administrable pharmaceutical formulation |
| WO2004032899A1 (en) * | 2002-10-08 | 2004-04-22 | Orchid Chemicals & Pharmaceuticals Ltd. | Antibiotic formulation for intramammary administration in milking animals |
| ES2300634T3 (es) | 2002-12-16 | 2008-06-16 | Intervet International Bv | Tratamiento de mastitis con una combinacion de prednisolona con cefalosporina. |
| US20080153894A1 (en) * | 2002-12-19 | 2008-06-26 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| WO2004057966A1 (en) | 2002-12-26 | 2004-07-15 | Solution Biosciences, Inc. | Compositions and methods for control of bovine mastitis |
| EP1607092A4 (en) | 2003-03-17 | 2010-12-15 | Takeda Pharmaceutical | CONTROLLED RELEASE COMPOSITIONS |
| US20090232899A1 (en) | 2004-05-21 | 2009-09-17 | David Allan E | Mucoadhesive nanocomposite delivery system |
| WO2006008640A1 (en) * | 2004-07-15 | 2006-01-26 | Pharmacia & Upjohn Company Llc | Non-aqueous suspension containing a drug having an unpleasant taste |
| KR100822519B1 (ko) | 2005-02-15 | 2008-04-16 | 주식회사종근당 | 위장 내에서 제어방출되는 단일 매트릭스 정제 |
| DE102007055341A1 (de) | 2007-11-19 | 2009-05-20 | Bayer Animal Health Gmbh | Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren |
| DK3064217T3 (en) * | 2009-01-06 | 2018-05-28 | Galenagen Llc | COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS |
| EP2373693A4 (en) * | 2009-01-06 | 2012-04-25 | Curelon Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI |
| WO2011009020A2 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| BRPI1002601E2 (pt) * | 2010-06-01 | 2020-06-30 | Embrapa Pesquisa Agropecuaria | composição nanoestruturada de uso veterinário para administração de fármacos |
-
2013
- 2013-02-27 ES ES13755420T patent/ES2740958T3/es active Active
- 2013-02-27 DK DK13755420.0T patent/DK2819699T3/da active
- 2013-02-27 RU RU2014135524A patent/RU2627429C2/ru active
- 2013-02-27 AU AU2013201147A patent/AU2013201147A1/en not_active Abandoned
- 2013-02-27 SI SI201331551T patent/SI2819699T1/sl unknown
- 2013-02-27 PL PL13755420T patent/PL2819699T3/pl unknown
- 2013-02-27 WO PCT/NZ2013/000022 patent/WO2013129944A1/en active Application Filing
- 2013-02-27 CN CN201380011138.5A patent/CN104244983A/zh active Pending
- 2013-02-27 MX MX2014010274A patent/MX366726B/es active IP Right Grant
- 2013-02-27 CN CN201910863593.7A patent/CN110604819A/zh active Pending
- 2013-02-27 CA CA2865555A patent/CA2865555C/en active Active
- 2013-02-27 KR KR1020147023706A patent/KR102100271B1/ko active IP Right Grant
- 2013-02-27 BR BR112014021218-0A patent/BR112014021218A2/pt not_active Application Discontinuation
- 2013-02-27 HU HUE13755420A patent/HUE045495T2/hu unknown
- 2013-02-27 JP JP2014558711A patent/JP6271443B2/ja active Active
- 2013-02-27 US US14/380,902 patent/US10828311B2/en active Active
- 2013-02-27 PT PT13755420T patent/PT2819699T/pt unknown
- 2013-02-27 EP EP13755420.0A patent/EP2819699B2/en active Active
-
2014
- 2014-08-21 CL CL2014002227A patent/CL2014002227A1/es unknown
- 2014-08-22 CR CR20140396A patent/CR20140396A/es unknown
- 2014-08-25 NI NI201400096A patent/NI201400096A/es unknown
- 2014-08-25 DO DO2014000195A patent/DOP2014000195A/es unknown
- 2014-08-26 CO CO14187211A patent/CO7061074A2/es unknown
- 2014-08-26 PH PH12014501919A patent/PH12014501919A1/en unknown
- 2014-08-26 ZA ZA2014/06267A patent/ZA201406267B/en unknown
- 2014-08-27 SV SV2014004796A patent/SV2014004796A/es unknown
-
2019
- 2019-08-02 HR HRP20191412 patent/HRP20191412T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191412T1 (hr) | Pripravci s kontroliranim oslobađanjem i postupci njihove upotrebe | |
| PE20171308A1 (es) | Forma de dosificacion que incluye una solucion solida de drogas amorfas | |
| HRP20191711T1 (hr) | Oftalmološki pripravak | |
| CO2018003558A2 (es) | Método de cristalización y biodisponibilidad | |
| BR112017008660A2 (pt) | formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf | |
| HRP20191366T4 (hr) | Injekcijski pripravak | |
| CL2019001447A1 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos. | |
| BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
| PH12018502615A1 (en) | Depot formulations | |
| AR106164A1 (es) | Proceso para preparar composiciones de recubrimiento termoselladas a base de agua | |
| MA44286A (fr) | Formulation pharmaceutique de cinéol et d'amoxicilline | |
| HRP20230615T1 (hr) | Čvrsti farmaceutski dozirni oblik za primjenu kao lijek u vodi za piće | |
| IL285073A (en) | Concentrated liquid pharmaceutical preparations of furosemide and methods of administering these preparations | |
| EP4279137A3 (en) | Oral pharmaceutical composition and method for producing particulate formulation comprising composition | |
| RU2015119243A (ru) | Твердые дисперсии нерастворимого лекарственного средства и способы их приготовления | |
| PH12019502322A1 (en) | Smectite suspension liqiud composition and method for preparing same | |
| WO2014147242A8 (en) | Piperaquine microcapsules and compositions containing them | |
| BRPI1010987B8 (pt) | composições de dosagem sólida de liberação controlada contendo ibuprofeno | |
| EA032385B9 (ru) | Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта | |
| WO2011151418A3 (en) | Nanosuspension formulation comprising a polydimethylsiloxane hydrophobic phase | |
| IL281217A (en) | Pharmaceutical preparation for controlled release of weak acid drugs and its uses | |
| EP4017458A4 (en) | METHOD AND COMPOSITION OF A NANOPARTICLE FORMULATION FOR SYSTEMIC TREATMENT OF SEPSIS | |
| JP2015034162A5 (hr) | ||
| MY175693A (en) | A method to produce slow release delivery carrier lipid nanoparticles of different log p value | |
| EP3600320A4 (en) | PROCEDURES AND COMPOSITIONS FOR THE SELF-REGULATED RELEASE OF PHARMACEUTICAL ACTIVE SUBSTANCES |